Pfizer says mid-stage trial data support monthly dosing for GLP-1 therapy
Source: SeekingAlpha
2026-06-06 10:09:29 ET
More on Pfizer
- Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
- Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy
- FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer
- Three studies used to justify U.S. vaccine policy under RFK Jr. face scrutiny: Guardian
- Pfizer in pact with Chai Discovery to use AI platform in drug development
Read the full article on Seeking Alpha
For further details see:
Pfizer says mid-stage trial data support monthly dosing for GLP-1 therapy
Eli Lilly and Company
NASDAQ: LLY
LLY Trading
1.0% G/L:
$1147.79 Last:
2,429,032 Volume:
$1143.38 Open:
LLY Latest News
June 07, 2026 11:00:00 am
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
June 06, 2026 03:35:00 pm
Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are Missing
June 06, 2026 02:30:00 pm
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 06, 2026 12:35:00 pm
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
LLY Stock Data
$977,526,804,738
935,929,919
9.81%
2658
N/A
Pharmaceuticals
Healthcare
US
Indianapolis
